Lecut Christelle, Peters Pierre, Massion Paul B, Gothot André
Laboratoire de thrombose-hémostase, Service d'hématologie biologique et immuno-hématologie, CHU Sart Tilman, Liège, Belgique.
Unité des soins intensifs, CHU Sart Tilman, Liège, Belgique.
Ann Biol Clin (Paris). 2015 Mar-Apr;73(2):137-49. doi: 10.1684/abc.2014.1018.
Laboratory diagnosis of coagulopathies primarily relies on assays selectively exploring either the extrinsic (PT), the intrinsic (aPTT) or the common (TT) pathway of the coagulation system. Although these tests are very useful to rapidly identify severe coagulation disorders or to monitor anticoagulant therapy, they only poorly correlate with the clinical manifestations. Global assays that evaluate the whole coagulation process could potentially more accurately reflect the hemorrhagic or thrombotic phenotype of an individual. Thrombin generation assay (TGA), first described in the 1950's, has been developed and automated in the 1990's. This technique is widely used in fundamental research but has yet failed to integrate clinical laboratories. In this article, we describe TGA and review its clinical applications. Laboratory aspects and technical issues will also be discussed.
凝血功能障碍的实验室诊断主要依赖于选择性检测凝血系统外源性(PT)、内源性(aPTT)或共同(TT)途径的检测方法。尽管这些检测对于快速识别严重凝血障碍或监测抗凝治疗非常有用,但它们与临床表现的相关性较差。评估整个凝血过程的整体检测方法可能更准确地反映个体的出血或血栓形成表型。凝血酶生成检测(TGA)最早于20世纪50年代被描述,在20世纪90年代得到发展并实现自动化。这项技术在基础研究中被广泛应用,但尚未整合到临床实验室中。在本文中,我们描述了TGA并综述了其临床应用。还将讨论实验室方面和技术问题。